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Cells respond to growth signals by activating internal 
programs that coordinate growth, division and death. One 
of these, the PI3K/AKT pathway, is frequently activated in 
human cancer (1). The serine/threonine kinase AKT is a 
key actor that regulates development, metabolism and the 
immune response (2,3).
Two decades of intense scrutiny have given us several 
AKT inhibitors to test as cancer therapeutics. Some have 
entered clinical trial, so it is important to define mechanisms 
underlying their therapeutic and toxic effects. Investigators 
frequently model the effects of an inhibitor with a germ-
line knockout (KO) of the inhibitor’s gene target in mice. 
However, we know that gene KO during development may 
mask a role in the adult. To study how adults respond to 
Akt loss, Wang et al. conditionally knocked out Akt in adult 
mice, both systemically and in the liver (4). This approach 
unmasked unexpected potential toxicities of AKT inhibitors.
The three members of the Akt family are Akt1, Akt2 
and Akt3. Their genetic sequences are quite similar, but 
we know they have both overlapping and distinct functions 
and substrates (5). Wang and colleagues find Akt1 and Akt3 
ablation does not kill adult mice. However, concomitant, 
systemic deletion of Akt1 and Akt2 cause liver inflammation, 
hypoglycemia and death. The authors speculate intestinal 
damage inhibits nutrient absorption, shifting the animal’s 
primary energy supply to fatty acid oxidation. Once the animal 
exhausts fat stores, hypoglycemia and death rapidly ensue. 
Effects of a moderately high dose of the pan AKT inhibitor 
MK2206 in mice are similar but reversible. Thus, this work 
illuminates a possible toxicity for pan AKT inhibitors.
The surprise in this study is that liver Akt1 ablation in 
adult Akt2−/− mice causes hepatocellular carcinoma (HCC). 
This was unexpected since Akt overexpression and pathway 
activation are implicated in HCC development (6-8). The 
authors find that Akt1 and Akt2 ablation increases liver 
injury and inflammation. Markers of proliferation are 
expressed within the hepatic tumors, while adjacent normal 
tissue expresses apoptotic markers. Thus Akt1 and Akt2 
deletion in livers of adult mice induces hepatocyte cell 
death and liver inflammation that progresses to HCC. AKT 
can suppress apoptosis by inhibiting FOXO transcription 
factors. This cascade is largely dependent on FoxO1 since 
deleting hepatic FoxO1 along with Akt1 and Akt2 protects 
mice from liver damage, inflammation and HCC.
The authors also investigate Akt1 and Akt2 involvement 
in liver tumor development using a chemically induced 
model of HCC. Individual knockout of Akt1 or Akt2 does 
not change the frequency of tumor induction. Rather 
Akt2 ablation increases HCC pulmonary metastasis. 
They speculate that high insulin levels in Akt2 KO mice 
increase Akt1 activation and metastasis. So here we see 
an unexpected potential negative side effect of inhibiting 
Akt2—accelerated HCC progression.
Previous work indicates overweight and obesity 
significantly increase the risk of HCC (9,10) through 
stimulation of liver damage and inflammation (11). These 
patients also have hepatic insulin resistance and decreased 
AKT signaling. This study implicates reduced hepatic AKT 
signaling in the genesis of obesity-induced HCC. One 
concern is that pan-AKT inhibitors that further suppress 
AKT signaling will exacerbate the increase in HCC seen in 
obese patients.
AKT inhibitors are slowly advancing through clinical 
trials. These results raise the possibility that pan AKT 
inhibitors cause liver injury and inflammation and possibly 
HCC. The work suggests that trials carefully monitor 
patients for liver damage and pro-tumorigenic side effects. 
We need further studies to determine whether there is 
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a window where benefits of AKT anti-tumor activity 
outweigh risk of these serious toxicities. Furthermore, we 
do not know whether drugs targeting other sites in the 
PI3K/AKT pathway will have similar side effects. Currently 
tested AKT inhibitors target all isoforms and include the 
ATP competitive inhibitor GSK690693 and allosteric 
inhibitor MK2206. Second generation allosteric inhibitors 
with isozyme specificity are under development and may 
reduce toxicities associated with pan AKT inhibitors.
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